Forte Capital LLC ADV boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 16.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,929 shares of the biopharmaceutical company’s stock after buying an additional 1,406 shares during the period. Forte Capital LLC ADV’s holdings in Pfizer were worth $340,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Fusion Family Wealth LLC purchased a new stake in Pfizer during the fourth quarter worth about $109,000. First National Bank Sioux Falls increased its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares in the last quarter. Stanford Investment Group Inc. increased its position in shares of Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares during the period. Cable Hill Partners LLC increased its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the period. Finally, Elite Wealth Management LLC bought a new position in shares of Pfizer during the third quarter worth about $164,000. Institutional investors and hedge funds own 70.82% of the company’s stock.
Shares of Pfizer, Inc. (PFE) traded up 0.49% during trading on Friday, reaching $32.97. The company’s stock had a trading volume of 31,878,571 shares. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $37.39. The company has a market capitalization of $196.76 billion, a PE ratio of 27.75 and a beta of 1.02. The stock has a 50 day moving average of $32.73 and a 200-day moving average of $33.02.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The business had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $13.09 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The business’s revenue was down 1.7% on a year-over-year basis. On average, analysts expect that Pfizer, Inc. will post $2.55 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 1st. Stockholders of record on Friday, May 12th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.88%. The ex-dividend date of this dividend was Wednesday, May 10th. Pfizer’s dividend payout ratio (DPR) is 108.48%.
COPYRIGHT VIOLATION WARNING: “Forte Capital LLC ADV Has $340,000 Stake in Pfizer, Inc. (PFE)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://transcriptdaily.com/2017/06/17/forte-capital-llc-adv-purchases-1406-shares-of-pfizer-inc-pfe-updated-updated.html.
A number of research analysts recently issued reports on PFE shares. Berenberg Bank set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Friday, February 17th. Jefferies Group LLC set a $34.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Friday, February 17th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $34.97 price objective for the company. in a research note on Thursday, February 23rd. Credit Suisse Group set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, March 13th. Finally, Sanford C. Bernstein set a $35.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, March 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $37.32.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.